Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study
- PMID: 21206546
- PMCID: PMC3014244
Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study
Abstract
Study objectives: To evaluate the effectiveness of ramelteon, a melatonin receptor agonist, for the treatment of insomnia in older adults starting auto-titrating positive airway pressure (APAP) therapy for sleep apnea.
Methods: A parallel group, randomized, double-blind, placebo-controlled pilot effectiveness clinical trial. The study enrolled 21 research study participants who were ≥ 60 years old and had obstructive sleep apnea, defined by an apnea-hypopnea index (AHI) ≥ 5 events/h, with complaints of insomnia. The primary outcome measure was change in sleep onset latency determined from polysomnography at 4 weeks. Research study participants, all of whom were starting on APAP, were randomized to ramelteon 8 mg (n = 8) or placebo (n = 13).
Results: Ramelteon treatment was associated with a statistically significant difference in sleep onset latency (SOL) as measured by polysomnography of 28.5 min (± 16.2 min) compared to placebo (95% C.I. 8.5 min to 48.6 min, effect size 1.35, p = 0.008). This was due to a 10.7 (± 17.0) min SOL reduction in the ramelteon arm and a 17.8 (± 23.5) min SOL increase in the placebo arm. No change was noted in subjective sleep onset latency (-1.3 min, ± 19.3 min, 95% C.I.: -21.4 min to 18.7 min). No statistically significant changes were noted in the AHI, sleep efficiency (polysomnography and self-report), APAP adherence, Pittsburgh Sleep Quality Index global score, or Epworth Sleepiness Scale score when comparing ramelteon vs. placebo. Four adverse events occurred in the ramelteon arm and 2 in the placebo arm; none were considered to be related to treatment.
Conclusions: Ramelteon was effective in improving objective, but not subjective, sleep onset latency even in older adults who were starting APAP therapy for sleep apnea. Further research is warranted in examining the role of ramelteon in the care of older adults with insomnia symptoms and sleep apnea.
Keywords: APAP; Insomnia; aged; polysomnography; ramelteon; sleep apnea.
Similar articles
-
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea.Sleep Breath. 2007 Sep;11(3):159-64. doi: 10.1007/s11325-006-0096-4. Sleep Breath. 2007. PMID: 17294232 Clinical Trial.
-
A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia.Curr Med Res Opin. 2007 May;23(5):1005-14. doi: 10.1185/030079907x178874. Curr Med Res Opin. 2007. PMID: 17519067 Clinical Trial.
-
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.J Clin Sleep Med. 2007 Aug 15;3(5):495-504. J Clin Sleep Med. 2007. PMID: 17803013 Free PMC article. Clinical Trial.
-
Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis.Sleep Med. 2014 Apr;15(4):385-92. doi: 10.1016/j.sleep.2013.11.788. Epub 2014 Feb 8. Sleep Med. 2014. PMID: 24656909 Review.
-
Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis.Int J Clin Pract. 2012 Sep;66(9):867-73. doi: 10.1111/j.1742-1241.2012.02987.x. Int J Clin Pract. 2012. PMID: 22897464 Review.
Cited by
-
Melatonin mediates intestinal barrier dysfunction and systemic inflammation in moderate-severe OSA patients.Ann Med. 2024 Dec;56(1):2361825. doi: 10.1080/07853890.2024.2361825. Epub 2024 Jul 8. Ann Med. 2024. PMID: 38973375 Free PMC article.
-
Effect of melatonin on insomnia and daytime sleepiness, in patients with obstructive sleep apnea and insomnia (COMISA): A randomized double-blinded placebo-controlled trial.J Pharm Health Care Sci. 2024 May 30;10(1):25. doi: 10.1186/s40780-024-00347-9. J Pharm Health Care Sci. 2024. PMID: 38816846 Free PMC article.
-
2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association.Sleep Sci. 2023 Nov 22;16(Suppl 2):507-549. doi: 10.1055/s-0043-1776281. eCollection 2023 Oct. Sleep Sci. 2023. PMID: 38370879 Free PMC article. Review.
-
Do Insomnia Treatments Improve Daytime Function?J Clin Med. 2023 Apr 24;12(9):3089. doi: 10.3390/jcm12093089. J Clin Med. 2023. PMID: 37176529 Free PMC article.
-
Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study.PLoS One. 2020 Sep 11;15(9):e0238723. doi: 10.1371/journal.pone.0238723. eCollection 2020. PLoS One. 2020. PMID: 32916693 Free PMC article.
References
-
- Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med. 2002;162:893–900. - PubMed
-
- Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6:97–111. - PubMed
-
- Beneto A, Gomez-Siurana E, Rubio-Sanchez P. Comorbidity between sleep apnea and insomnia. Sleep Med Rev. 2009 - PubMed
-
- Johansson P, Alehagen U, Svanborg E, Dahlstrom U, Brostrom A. Sleep disordered breathing in an elderly community-living population: Relationship to cardiac function, insomnia symptoms and daytime sleepiness. Sleep Med. 2009;10:1005–11. - PubMed
-
- Lichstein KL, Riedel BW, Lester KW, Aguillard RN. Occult sleep apnea in a recruited sample of older adults with insomnia. J Consult Clin Psychol. 1999;67:405–10. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical